Regulation of tissue factor expression in smooth muscle cells with nitric oxide

Journal of Vascular Surgery

Volumn 37, Issue 3, 2003, Pages 650-659

  Kibbe, Melina R ^a   Johnnides, Christopher ^a   Gleixner, Susan ^a   Kovesdi, Imre ^b   Lizonova, Alena ^b   Zuckerbraun, Brian ^a   Billiar, Timothy R ^a   Tzeng, Edith ^a   Muluk, Satish C ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b GENVEC INC   (United States)

^c Department of Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MUTANT PROTEIN; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PYRROLIDINE DITHIOCARBAMATE; THROMBOPLASTIN;

ANIMAL CELL; AORTA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 0037344294     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2003.140     Document Type: Article

References (48)

1. Osterud B. Tissue factor: A complex biological role [review]. Thromb Haemost 1997;78:755-8.
2. Vallet B. Microthrombosis in sepsis [review]. Minerva Anesthesiol 2001;67:298-301.
3. Rapaport SI, Rao VM. The tissue factor pathway: How it has become a "prima ballerina". Thromb Haemost 1995;74:7-17.
4. Vallance P, Chan N. Endothelial function and nitric oxide: Clinical relevance [review]. Heart 2001;85:342-50.
5. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury [review]. Cardiovasc Res 1999;43:650-7.
6. Volk T, Kox WJ. Endothelium function in sepsis [review]. Inflamm Res 2000;49:185-98.
7. Hack CE, Zeerleder S. The endothelium in sepsis: Source of and a target for inflammation [review]. Crit Care Med 2001;29(suppl):S21-7.
8. Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function [review]. Med Sci Monitor 2001;7:1075-85.
9. Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? [Review; 404 references. Pharmacol Ther 2001;91:179-213.
10. Hierholzer C, Harbrecht B, Menezes JM, Kane J, MacMicking J, Nathan, et al. Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med 1998;187:917-28.
11. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997;95:1269-77.
12. 2+ mobilization and protein kinase C activation. J Clin Invest 1993;91:547-52.
13. Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 1993;90:3491-5.
14. Shears LL, Kibbe MR, Murdock AD, Billiar TR, Lizonova A. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295-306.
15. Uesugi T, Froh M, Arteel GE, Bradford BU, Gabele E, Wheeler MD, et al. Delivery Of IκB superrepressor gene with adenovirus reduces early alcohol-induced liver injury in rats. Hepatology 2001;34:1149-57.
16. Kibbe M, Nie S, Watkins S, Lizonova A, Kovesdi I, Simmons RL, et al. Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg 2000;31:1214-28.
17. Tzeng E, Yoneyama T, Hatakeyama K, Shears LL, Billiar TR. Vascular inducible nitric oxide synthase gene therapy: Requirement for guanosine triphosphate cyclohydrolase I. Surgery 1996;120:315-21.
18. Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA, Wang, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 1993;90:522-6.
19. Fisher KL, Gorman CM, Vehar GA, O'Brien DP, Lawn RM. Cloning and expression of human tissue factor cDNA. Thromb Res 1987;48:89-99.
20. Morrissey JH, Neuenschwander PF, Huang Q, McCallum CD, Su B. Factor VIIa-tissue factor: Functional importance of protein-membrane interactions [review]. Thromb Haemost 1997;78:112-6.
21. Semeraro N, Colucci M. Tissue factor in health and disease [review]. Thromb Haemost 1997;78:759-64.
22. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989;134:1087-97.
23. Szabo C, Billiar TR. Novel roles of nitric oxide in hemorrhagic shock [review]. Shock 1999;12:1-9.
24. Kobayashi T, Gabazza EC, Shimizu S, Yasui H, Yuda H, Hataji O. Long-term inhalation of high-dose nitric oxide increases intraalveolar activation of coagulation system in mice. Am J Respir Crit Care Med 2001;163:1676-82.
25. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000;101:2144-8.
26. Gerlach M, Keh D, Bezold G, Spielmann S, Kurer I, Peter RU, et al. Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite. Intens Care Med 1998;24:1199-208.
27. Corseaux D, Le Tourneau T, Six I, Ezekowitz MD, Mc FE. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: Inhibition with dietary L-arginine. Circulation 1998;98:1776-82.
28. Polack B, Pernod G, Barro C, Doussiere J. Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis 1997;27:193-200.
29. Arnelle DR, Stamler JS. NO+, NO, and NO- donation by S-nitrosothiols: Implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch Biochem Biophys 1995;318:279-85.
30. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D. Role of NFκB in the mortality of sepsis. J Clin Invest 1997;100:972-85.
31. Mackman N, Brand K, Edgington TS. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J Exp Med 1991;174:1517-26.
32. Orthner CL, Rodgers GM, Fitzgerald LA. Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: Evidence implicating nuclear factor-kappa B in TF induction by diverse agonists. Blood 1995;86:436-43.
33. Hall AJ, Vos HL, Bertina RM. Lipopolysaccharide induction of tissue factor in THP-1 cells involves Jun protein phosphorylation and nuclear factor kappaB nuclear translocation. J Biol Chem 1999;274:376-83.
34. Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB [review]. Free Radical Biol Med 2000;28:1317-27.
35. Marshall HE, Stamler JS. Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (NF)-kappaB [review]. Am J Respir Cell Molec Biol 1902;21:296-7.
36. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proceedings of the National Academy of Sciences of the United States of America 1989;86:2839-43.
37. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-32.
38. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation 1996;94:3090-7.
39. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscl Thromb Vasc Biol 1997;17:2479-88.
40. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996;75:77-85.
41. Radomski MW, Salas E. Nitric oxide: Biological mediator, modulator and factor of injury; its role in the pathogenesis of atherosclerosis [review]. Atherosclerosis 1995;118(suppl):S69-80.
42. Wang BY, Ho HK, Lin PS, Schwarzacher SP, Pollman MJ, Gibbons GH. Regression of atherosclerosis: Role of nitric oxide and apoptosis. Circulation 1999;99:1236-41.
43. Fuster V, Badimon J, Chesebro JH, Fallon JT. Plaque rupture, thrombosis, and therapeutic implications [review]. Haemostasis 1996;26(suppl 4):269-84.
44. Yan ZQ, Yokota T, Zhang W, Hansson GK. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res 1996;79:38-44.
45. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993;91:2253-9.
46. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 1995;92:3323-30.
47. Courtman DW, Schwartz SM, Hart CE. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass: Extrinsic pathway inhibition eliminates luminal narrowing. Circ Res 1998;82:996-1006.
48. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe, et al. Tissue factor in the pathogenesis of atherosclerosis [review]. Thromb Haemost 1997;78:200-4.